EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Next steps

Stage 3: What evidence should you request from each pharmacy or supplier?

Dose Diligence research deskSection 12 · Page 4 of 11Last updated 17 Nov 2026

Ask a small number of qualified candidates to answer the same evidence request. A suggested starting point is two or three candidates plus the incumbent, where relevant—not an unrestricted supplier directory.

Maintain an evidence register with these fields:

Claim | Legal entity | Facility | Product/route | State | Source | Evidence date | Status | Unresolved question | Owner

Use four statuses: independently verified fact, supplier assertion, buyer assumption, specialist review required. “Not retrieved” should remain unknown, not become either a clean bill of health or an adverse finding.

Supplier due-diligence checklist

AreaRequest and verification taskDecision implication
Identity and licensingMatch contract entity, dispensing facility, address and relevant licence records. California’s lookup distinguishes pharmacy, sterile-compounding, nonresident sterile-compounding and outsourcing categories.A familiar trading name is insufficient; assess the actual facility and relevant permission. (pharmacy.ca.gov)
Inspection and enforcementReview FDA records where applicable, state disciplinary records, supplier responses and corrective-action evidence.FDA’s outsourcing register does not include all state actions; a Form 483 is not a final agency determination of a violation. (fda.gov)
Compounding historySearch FDA’s inspections, recalls and other-actions records using the facility and associated names.Ask a qualified reviewer to assess findings and remediation relevant to the proposed work. (fda.gov)
Product identity and handlingRequest specimen labels, formulation details where relevant, dosing materials, storage instructions and complaint procedures.FDA has identified fraudulent labelling, dosing errors and concerns about semaglutide salt forms in unapproved products. (fda.gov)
Approved-drug provenanceAsk the responsible trading partner to demonstrate applicable supplier verification, tracing and suspect-product procedures.FDA identifies these as core DSCSA responsibilities for pharmacies. Determine your clinic’s own role separately. (fda.gov)
Shipping and excursionsRequest product-specific packaging qualification, shipping rules, excursion assessment, replacement responsibility and complaint escalation.FDA has reported concerns about compounded injectable GLP-1 products arriving inadequately refrigerated. (fda.gov)
Operational capabilityRequest recent aggregate acceptance, clarification, dispensing and delivery data; capacity assumptions; allocation rules; escalation contacts; and a sample reporting export.Treat claimed performance as unverified until supported by records or a controlled pilot.

Do not use an outdated DSCSA deadline as a procurement shortcut. FDA’s August 6, 2026 letter extends specified small-business-dispenser exemptions through November 27, 2027; it does not exempt qualifying organisations from every DSCSA obligation. Have the relevant specialist establish applicability to the actual entity and transaction. (fda.gov)

What should the multi-state coverage matrix contain?

Build one row for each facility × destination state × product route:

  • Relevant permission and independently checked source.
  • Licence status, expiry and disciplinary-review status.
  • Written confirmation that the pharmacy accepts the proposed prescriptions.
  • Delivery limitations, operating cutoffs and patient-support availability.
  • Confirmed capacity for the intended launch volume.
  • Responsible owner and unresolved launch conditions.

Exit test: clinical, legal and operational approvers can distinguish evidence from marketing claims. A “nationwide” statement is not the matrix.

Explore the table row by row

A working view of the research

Identity and licensing

Request and verification task
Match contract entity, dispensing facility, address and relevant licence records. California’s lookup distinguishes pharmacy, sterile-compounding, nonresident sterile-compounding and outsourcing categories.
Decision implication
A familiar trading name is insufficient; assess the actual facility and relevant permission. (pharmacy.ca.gov)

Sources cited on this page

  1. pharmacy.ca.gov · Source 1 ↗https://www.pharmacy.ca.gov/about/verify_lic
  2. fda.gov · Source 2 ↗https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
  3. fda.gov · Source 3 ↗https://www.fda.gov/drugs/human-drug-compounding/compounding-inspections-recalls-and-other-actions
  4. fda.gov · Source 4 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  5. fda.gov · Source 5 ↗https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/pharmacists-utilize-dscsa-requirements-protect-your-patients
  6. fda.gov · Source 6 ↗https://www.fda.gov/media/194424/download
Section sources →